NOTE

Crucial Role of Insulin in Leptin Maintenance: Profound Decrease in Serum Leptin by Octreotide Acetate in Insulinoma Subjects

TOMOATSU NAKAMURA, SHOICHIRO NAGASAKA, SAN-E ISHIKAWA, MUTSUO NONAKA, KAZUTOSHI FUJIBAYASHI, TAKAKO SAITO, IKUYO KUSAKA, MINORI HIGASHIYAMA AND TOSHIKAZU SAITO

Division of Endocrinology and Metabolism, Department of Medicine, Jichi Medical School, Tochigi 329-0498, Japan

Abstract. To further clarify the relationship between insulin and leptin, time course changes in plasma glucose, serum insulin and leptin levels were analyzed after subcutaneous administration of 100 μg octreotide acetate in two insulinoma subjects. Octreotide acetate induced a prompt decrease in serum insulin level, accompanied with an increase in plasma glucose in both patients. Following the decrease in serum insulin level, serum leptin concentrations were profoundly decreased by 66% and 44%, 8–12 hrs after octreotide injection; that is, the concentrations decreased from 41.1 to 13.8 ng/ml in patient 1, and from 17.5 to 9.8 ng/ml in patient 2. Daily profiles of plasma glucose, serum insulin and leptin without octreotide administration did not show such alterations in these indexes in patient 1. These data show that circulating leptin may be susceptible to decline dependent on the decrease in serum insulin, suggesting that insulin plays a crucial role in the maintenance of leptin secretion in humans.

Key words: Leptin, Insulin, OH, Octreotide acetate, Insulinoma

INSULIN increases leptin mRNA in isolated adipocytes [1, 2], and close correlations have been demonstrated between insulin and leptin. In humans, both serum insulin and leptin concentrations rise higher in accordance with an increase in body mass index (BMI) [3]. Although it is still controversial whether the association between insulin and leptin reflects a direct causal relationship or is merely mediated by coexisting hyperinsulinemia and greater fat mass in obesity, recent data seem to favor the former possibility. Hyperinsulinemia closely associates with serum leptin in insulinoma subjects, and both hyperinsulinemia and hyperleptinemia ameliorate after the surgical removal of the insulinomas [4, 5]. Diabetic subjects treated with insulin also had higher leptin concentrations than those treated without insulin [6].

Apart from these observations in chronic phase, leptin mRNA expression in vivo is promptly increased by feeding in rodents [1]. This postprandial increase might be attributed to the direct action of insulin, and is thought to participate in regulating food intake and energy expenditure in rodents [1]. In contrast, leptin mRNA expression can be enhanced in human adipocytes only after incubation with insulin for longer than 72 hrs [2, 7], and prolonged and supraphysiological insulinemia is necessary to significantly increase serum leptin in healthy subjects [2] and in type 1 diabetic patients with ketoacidosis or ketosis [8, 9]. These results suggest that leptin secretion is robust against stimu-
lation by insulin in humans. On the other hand, fasting induces a greater decline in serum leptin than the expected by a decrease in body fat [10]. To clarify the role of insulin in leptin maintenance, we examined the acute effect of a long-acting somatostatin analogue, octreotide acetate, on serum leptin levels in two insulinoma subjects, and found a rapid and drastic decrease in serum leptin, following the decrease in insulin levels.

**Subjects and Methods**

**Subjects**

Patient 1. A 59-year-old man, with a BMI of 39.4 kg/m², was found to have hypoglycemia and concomitant hyperinsulinemia by the survey of unconsciousness. During intravenous glucose infusion, plasma glucose and serum insulin levels were 1.9 mmol/l and 1220 pmol/l, respectively. Serum leptin concentration was as high as 104 ng/ml. Abdominal echogram and computed tomography demonstrated a 3.0 cm hypervascular mass in the pancreatic body, which was later confirmed as an insulinoma by surgical procedure. For relief from hypoglycemic symptoms, octreotide acetate 12.5 μg was administered twice daily, and octreotide acetate challenge was performed under this condition.

Patient 2. A 60-year-old woman, with a BMI of 28.1 kg/m², was referred to our division for the evaluation of hypoglycemia. Her fasting plasma glucose and insulin levels were 2.0 mmol/l and 122 pmol/l, respectively. The ratio of fasting insulin to glucose (Fajans index) was 0.57 (normal upper limit is 0.30). Abdominal echogram revealed a 1.6 cm low echoic mass in the pancreatic body. Intra-arterial stimulation with calcium (0.025 mEq Ca²⁺/kg body weight) into the proximal splenic artery produced a twenty-fold elevation in insulin levels in the right hepatic vein at 30 seconds, while injection of calcium into the gastroduodenal, distal splenic, and hepatic artery failed to demonstrate the insulin gradients [11].

**Octreotide acetate challenge**

In both patients, time course changes in plasma glucose, serum insulin, leptin and GH levels were analyzed after a subcutaneous administration of 100 μg octreotide acetate (Sandostatin®, Sandoz, Switzerland) at 0800 h. Briefly, blood collections were made at intervals of 4 hrs for 20 hrs. Breakfast and lunch were allowed at 0800 h and at 1200 h after the blood sampling, respectively, and dinner at 1800 h. In patient 1, the time course changes in plasma glucose, serum insulin and leptin levels were also determined without octreotide acetate. The protocol was approved by the local ethical committee of Jichi Medical School, and informed consent for collection of blood was obtained from the two patients.

**Measurements**

Plasma glucose concentrations were measured by the glucose-oxidase method. Serum insulin and GH concentrations were determined by insulin and GH RIA kits, and serum leptin by leptin RIA kits (Linco Research Inc., St. Charles, MO). The intra- and inter-assay coefficients of variation were less than 5% for leptin.

**Statistical analysis**

In patient 1, the relationship between serum insulin and leptin was assessed by linear regression analysis using the statistical package of StatView for Macintosh, version 4.1. A p-value less than 0.05 was considered significant.

**Results**

In patient 1, 100 μg octreotide acetate induced a prompt decrease in serum insulin, accompanied with an increase in plasma glucose (Fig. 1B). Following the decrease in serum insulin, serum leptin levels were also profoundly decreased from 41.1 to 13.8 ng/ml (by 66%) 12 hrs after the octreotide administration. Serum GH concentration was suppressed from 1.3 to less than 0.2 ng/ml during octreotide challenge (Fig. 1B). Daily changes in plasma glucose, serum insulin and leptin levels did not show such alterations on the day without octreotide acetate (Fig. 1A). After tumor resection, plasma glucose level increased to 5.2 mmol/l, and serum insulin and leptin concentrations decreased to 36 pmol/l and 8.6 ng/ml, respec-
In this condition, the subcutaneous injection of 100 µg octreotide acetate decreased serum insulin level from 36 to 25 pmol/l (by 31%) after 4 hrs, followed by decrease in serum leptin concentration from 8.6 to 6.4 ng/ml (by 26%) after 8 hrs (Fig. 1C). During these investigations, serum insulin and leptin levels were simultaneously measured in the 48 samples: 24 samples during the baseline period, 17 by the octreotide challenge, and 7 by the challenge after tumor resection. There was a close positive correlation between serum insulin and leptin levels both in the overall samples (n = 48, r = 0.899, P < 0.0001) and in the samples of octreotide acetate treatment (n = 24, r = 0.750, P < 0.0001) (Fig. 2).

In patient 2, 100 µg octreotide acetate decreased serum insulin level from 97 to 30 pmol/l and increased plasma glucose from 2.2 to 17.1 mmol/l after 4 hrs. Serum leptin concentration was decreased from 17.5 to 9.8 ng/ml (by 44%) 8 hrs after octreotide administration. Serum GH levels fluctuated between 0.1 and 1.5 ng/ml (Fig. 3).

**Discussion**

After the subcutaneous administration of 100 µg octreotide acetate, the serum insulin levels were markedly decreased, accompanied with an increase in plasma glucose in the two insulinoma subjects. Following the decrease in insulin, rapid and profound reduction in serum leptin levels was observed. In contrast, such alterations in plasma glucose, serum insulin and leptin levels were not observed in the daily profiles without octreotide administration in patient 1. Thus, it appears that the acute fall in serum insulin resulted in a decrease in serum leptin levels.
in these two subjects. We observed a close association between serum insulin and leptin levels in patient 1, which was not disturbed by octreotide administration (Fig. 2). These results also suggest that somatostatin promptly reduces serum leptin levels probably through a decrease in serum insulin.

However, several factors should be considered which could affect the relationship of insulin and leptin in the present study. First, somatostatin suppresses GH secretion from anterior pituitary gland [12], and serum leptin concentrations are elevated in GH-deficient hypopituitary adults [13]. We found slight decreases in serum GH concentrations during octreotide challenge, but the decreases were minor.

Fig. 2. Relationship between serum insulin and leptin levels in patient 1, which were simultaneously measured during the baseline period (○, n=24), by octreotide acetate treatment before (+, n=17) and after tumor resection (△, n=7).

Fig. 3. Time-course changes in plasma glucose (●), serum insulin (■), GH (○), and leptin (□) by octreotide acetate treatment in patient 2. Arrow shows subcutaneous administration of 100 μg octreotide acetate.
and inconsistent with the marked decrease in serum leptin. Secondly, Donahoo et al. [14] suggest that somatostatin may have a direct suppressive effect on serum leptin concentrations. Due to the observational nature of the present study, such a direct effect of somatostatin cannot be fully excluded. Further study is needed to clarify the direct effect of somatostatin on leptin production in adipocytes.

In Figure 2, the correlation between serum insulin and leptin levels seems solid up to a serum insulin concentration of 1000 pmol/l, but a further increase in serum insulin no longer raised serum leptin level. In this subject, extreme hyperinsulinemia was frequently associated with severe hypoglycemia. Hypoglycemia per se may limit further increase in serum leptin concentration, since an influx of glucose is an important signal which regulates leptin secretion from adipocytes [15]. As some studies showed that glucose uptake by fat and muscle was not changed in vitro [16], or even increased in fasting dogs [17], by somatostatin administration, it is unlikely that somatostatin can affect an influx of glucose, thereby reducing circulating leptin levels.

It is well known that fasting induces a decline in serum leptin. We have also confirmed that serum leptin concentrations gradually decreased to about 33–47% of the initial values during 48 hr fasting in obese and normal-weight volunteers [9]. Simultaneously, serum insulin levels were decreased to about 32–51% of the initial values [9]. Saad et al. [18] revealed that a very low dose insulin infusion could abolish such a decline in serum leptin during 9 hr fasting. The present results, together with these data, indicate that circulating leptin is susceptible to decline, presumably dependent on the decrease in serum insulin. In contrast, the prevailing observations from human studies suggest that leptin secretion is rather robust against the acute stimulation by insulin, as mentioned in the introduction [2, 7–9]. These characteristics of the relationship between insulin and leptin in humans seem favorable to gain and maintain body fat, together with the well-described “leptin resistance” in obesity. An insulin-leptin system may be constructed as a part of “thrifty genes” in humans.

References


